Market Research Logo

Santen Pharmaceutical Co., Ltd. - Product Pipeline Review - 2015

Santen Pharmaceutical Co., Ltd. - Product Pipeline Review - 2015

Summary

Global Markets Direct’s, ‘Santen Pharmaceutical Co., Ltd. - Product Pipeline Review - 2015’, provides an overview of the Santen Pharmaceutical Co., Ltd.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Santen Pharmaceutical Co., Ltd.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Santen Pharmaceutical Co., Ltd. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Santen Pharmaceutical Co., Ltd.’s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Santen Pharmaceutical Co., Ltd.’s pipeline products
Reasons to buy
  • Evaluate Santen Pharmaceutical Co., Ltd.’s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Santen Pharmaceutical Co., Ltd. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Santen Pharmaceutical Co., Ltd.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Santen Pharmaceutical Co., Ltd. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Santen Pharmaceutical Co., Ltd.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Santen Pharmaceutical Co., Ltd. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues


Santen Pharmaceutical Co., Ltd. Snapshot
Santen Pharmaceutical Co., Ltd. Overview
Key Information
Key Facts
Santen Pharmaceutical Co., Ltd. - Research and Development Overview
Key Therapeutic Areas
Santen Pharmaceutical Co., Ltd. - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Combination Treatment Modalities
Pipeline Products - Partnered Products
Partnered Products/Combination Treatment Modalities
Santen Pharmaceutical Co., Ltd. - Pipeline Products Glance
Santen Pharmaceutical Co., Ltd. - Late Stage Pipeline Products
Pre-Registration Products/Combination Treatment Modalities
Filing rejected/Withdrawn Products/Combination Treatment Modalities
Phase III Products/Combination Treatment Modalities
Santen Pharmaceutical Co., Ltd. - Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Santen Pharmaceutical Co., Ltd. - Early Stage Pipeline Products
Preclinical Products/Combination Treatment Modalities
Santen Pharmaceutical Co., Ltd. - Drug Profiles
(tafluprost + timolol maleate)
Product Description
Mechanism of Action
R&D Progress
diquafosol tetrasodium
Product Description
Mechanism of Action
R&D Progress
sirolimus
Product Description
Mechanism of Action
R&D Progress
tafluprost
Product Description
Mechanism of Action
R&D Progress
levofloxacin
Product Description
Mechanism of Action
R&D Progress
cyclosporine
Product Description
Mechanism of Action
R&D Progress
DE-117
Product Description
Mechanism of Action
R&D Progress
DE-120
Product Description
Mechanism of Action
R&D Progress
latanoprost
Product Description
Mechanism of Action
R&D Progress
lomerizine
Product Description
Mechanism of Action
R&D Progress
dexamethasone dipropionate
Product Description
Mechanism of Action
R&D Progress
SA-14867
Product Description
Mechanism of Action
R&D Progress
TRC-105
Product Description
Mechanism of Action
R&D Progress
Santen Pharmaceutical Co., Ltd. - Pipeline Analysis
Santen Pharmaceutical Co., Ltd. - Pipeline Products by Target
Santen Pharmaceutical Co., Ltd. - Pipeline Products by Route of Administration
Santen Pharmaceutical Co., Ltd. - Pipeline Products by Molecule Type
Santen Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action
Santen Pharmaceutical Co., Ltd. - Recent Pipeline Updates
Santen Pharmaceutical Co., Ltd. - Dormant Projects
Santen Pharmaceutical Co., Ltd. - Dormant Projects
Santen Pharmaceutical Co., Ltd. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
DE-102
DE-104
DE-105
evodenoson
gefarnate
olmesartan
ONO-6126
rivoglitazone
Santen Pharmaceutical Co., Ltd. - Company Statement
Santen Pharmaceutical Co., Ltd. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Santen Pharmaceutical Co., Ltd., Key Information
Santen Pharmaceutical Co., Ltd., Key Facts
Santen Pharmaceutical Co., Ltd. - Pipeline by Indication, 2015
Santen Pharmaceutical Co., Ltd. - Pipeline by Stage of Development, 2015
Santen Pharmaceutical Co., Ltd. - Monotherapy Products in Pipeline, 2015
Santen Pharmaceutical Co., Ltd. - Combination Treatment Modalities in Pipeline, 2015
Santen Pharmaceutical Co., Ltd. - Partnered Products in Pipeline, 2015
Santen Pharmaceutical Co., Ltd. - Partnered Products/ Combination Treatment Modalities, 2015
Santen Pharmaceutical Co., Ltd. - Pre-Registration, 2015
Santen Pharmaceutical Co., Ltd. - Filing rejected/Withdrawn, 2015
Santen Pharmaceutical Co., Ltd. - Phase III, 2015
Santen Pharmaceutical Co., Ltd. - Phase II, 2015
Santen Pharmaceutical Co., Ltd. - Phase I, 2015
Santen Pharmaceutical Co., Ltd. - Preclinical, 2015
Santen Pharmaceutical Co., Ltd. - Pipeline by Target, 2015
Santen Pharmaceutical Co., Ltd. - Pipeline by Route of Administration, 2015
Santen Pharmaceutical Co., Ltd. - Pipeline by Molecule Type, 2015
Santen Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action, 2015
Santen Pharmaceutical Co., Ltd. - Recent Pipeline Updates, 2015
Santen Pharmaceutical Co., Ltd. - Dormant Developmental Projects,2015
Santen Pharmaceutical Co., Ltd. - Discontinued Pipeline Products, 2015
Santen Pharmaceutical Co., Ltd., Other Locations
Santen Pharmaceutical Co., Ltd., Subsidiaries
List of Figures
Santen Pharmaceutical Co., Ltd. - Pipeline by Top 10 Indication, 2015
Santen Pharmaceutical Co., Ltd. - Pipeline by Stage of Development, 2015
Santen Pharmaceutical Co., Ltd. - Monotherapy Products in Pipeline, 2015
Santen Pharmaceutical Co., Ltd. - Partnered Products in Pipeline, 2015
Santen Pharmaceutical Co., Ltd. - Pipeline by Top 10 Target, 2015
Santen Pharmaceutical Co., Ltd. - Pipeline by Top 10 Route of Administration, 2015
Santen Pharmaceutical Co., Ltd. - Pipeline by Top 10 Molecule Type, 2015
Santen Pharmaceutical Co., Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report